NASDAQ:EGRX

Eagle Pharmaceuticals Stock Forecast, Price & News

$42.89
-0.55 (-1.27 %)
(As of 06/18/2021 12:00 AM ET)
Add
Compare
Today's Range
$42.20
$43.71
50-Day Range
$36.86
$44.50
52-Week Range
$36.48
$53.43
Volume385,942 shs
Average Volume116,949 shs
Market Capitalization$562.25 million
P/E Ratio40.46
Dividend YieldN/A
Beta0.78
30 days | 90 days | 365 days | Advanced Chart
Receive EGRX News and Ratings via Email

Sign-up to receive the latest news and ratings for Eagle Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Eagle Pharmaceuticals logo

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc., a biotechnology pharmaceutical company, focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also includes EP-4104, a dantrolene sodium for exertional heat stroke, as well as to treat organophosphate exposure; EP-5101 (PEMFEXY) for lung cancer and mesothelioma; EGL-5385-C-1701 (fulvestrant) for breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has a strategic collaboration with Tyme Technologies, Inc. to advance oral SM-88 for the treatment of patients with cancer. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Headlines

Eagle Pharmaceuticals (NASDAQ:EGRX) Shares Gap Up to $40.84
Eagle Pharmaceuticals (NASDAQ:EGRX) Shares Gap Up to $40.84
May 27, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.41 out of 5 stars

Medical Sector

705th out of 2,097 stocks

Pharmaceutical Preparations Industry

343rd out of 831 stocks

Analyst Opinion: 0.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 2.5 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Eagle Pharmaceuticals (NASDAQ:EGRX) Frequently Asked Questions

What stocks does MarketBeat like better than Eagle Pharmaceuticals?

Wall Street analysts have given Eagle Pharmaceuticals a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Eagle Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Eagle Pharmaceuticals' next earnings date?

Eagle Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Eagle Pharmaceuticals
.

How were Eagle Pharmaceuticals' earnings last quarter?

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) issued its quarterly earnings results on Monday, May, 10th. The specialty pharmaceutical company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.20 by $0.04. The specialty pharmaceutical company had revenue of $41.25 million for the quarter, compared to analysts' expectations of $45.67 million. Eagle Pharmaceuticals had a trailing twelve-month return on equity of 7.87% and a net margin of 7.89%.
View Eagle Pharmaceuticals' earnings history
.

How has Eagle Pharmaceuticals' stock been impacted by COVID-19?

Eagle Pharmaceuticals' stock was trading at $39.07 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, EGRX stock has increased by 9.8% and is now trading at $42.89.
View which stocks have been most impacted by COVID-19
.

Who are Eagle Pharmaceuticals' key executives?

Eagle Pharmaceuticals' management team includes the following people:
  • Mr. Scott L. Tarriff, Founder, Pres, CEO & Director (Age 61, Pay $2.33M)
  • Mr. David M. Pernock, Chief Operating Officer (Age 68, Pay $1.28M)
  • Mr. Brian Joseph Cahill, Chief Financial Officer (Age 52)
  • Mr. Daniel O'Connor, Exec. VP, Chief Strategy Officer & Head of Corp. Devel. (Age 41)
  • Mr. Michael Moran, Exec. VP and Head of Sales, Bus. Devel. & Gov. Affairs
  • Dr. Judith Ng-Cashin, Exec. VP & Chief Medical Officer (Age 52)
  • Mr. John Kimmet, Exec. VP of Marketing Oncology & Acute Care
  • Dr. Valentin R. Curt M.D., Sr. VP of Clinical Drug Devel.
  • Dr. Gaozhong Zhu Ph.D., Sr. VP of Pharmaceutical Devel.
  • Mr. Reiner Nowak, Exec.

Who are some of Eagle Pharmaceuticals' key competitors?

What other stocks do shareholders of Eagle Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eagle Pharmaceuticals investors own include Gilead Sciences (GILD), Exelixis (EXEL), Teekay Tankers (TNK), AbbVie (ABBV), Intercept Pharmaceuticals (ICPT), Radius Health (RDUS), bluebird bio (BLUE), Clovis Oncology (CLVS), GW Pharmaceuticals (GWPH) and Incyte (INCY).

What is Eagle Pharmaceuticals' stock symbol?

Eagle Pharmaceuticals trades on the NASDAQ under the ticker symbol "EGRX."

Who are Eagle Pharmaceuticals' major shareholders?

Eagle Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (15.10%), Janus Henderson Group PLC (12.13%), Brandes Investment Partners LP (3.74%), Park West Asset Management LLC (3.43%), Dimensional Fund Advisors LP (2.50%) and Smith Graham & Co. Investment Advisors LP (2.37%).
View institutional ownership trends for Eagle Pharmaceuticals
.

Which institutional investors are selling Eagle Pharmaceuticals stock?

EGRX stock was sold by a variety of institutional investors in the last quarter, including Park West Asset Management LLC, Armistice Capital LLC, Citadel Advisors LLC, Janus Henderson Group PLC, Morgan Stanley, Prudential Financial Inc., State Board of Administration of Florida Retirement System, and Renaissance Technologies LLC.
View insider buying and selling activity for Eagle Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Eagle Pharmaceuticals stock?

EGRX stock was bought by a variety of institutional investors in the last quarter, including Brandes Investment Partners LP, Smith Graham & Co. Investment Advisors LP, Kennedy Capital Management Inc., D. E. Shaw & Co. Inc., Acadian Asset Management LLC, Man Group plc, BlackRock Inc., and Federated Hermes Inc..
View insider buying and selling activity for Eagle Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Eagle Pharmaceuticals?

Shares of EGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eagle Pharmaceuticals' stock price today?

One share of EGRX stock can currently be purchased for approximately $42.89.

How much money does Eagle Pharmaceuticals make?

Eagle Pharmaceuticals has a market capitalization of $562.25 million and generates $187.80 million in revenue each year. The specialty pharmaceutical company earns $11.99 million in net income (profit) each year or $0.87 on an earnings per share basis.

How many employees does Eagle Pharmaceuticals have?

Eagle Pharmaceuticals employs 106 workers across the globe.

What is Eagle Pharmaceuticals' official website?

The official website for Eagle Pharmaceuticals is www.eagleus.com.

Where are Eagle Pharmaceuticals' headquarters?

Eagle Pharmaceuticals is headquartered at 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677.

How can I contact Eagle Pharmaceuticals?

Eagle Pharmaceuticals' mailing address is 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677. The specialty pharmaceutical company can be reached via phone at 201-326-5300 or via email at [email protected]


This page was last updated on 6/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.